Showing results (21-30 of 36) with videos related to
Sort By:
Pageof 4
Cancer Immunology Research|January 18, 2019
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid TumorsRobin Parihar, Charlotte Rivas, Mai Huynh, et al.Cellular Immunology|October 17, 2002
Administration of two macrophage-derived interferon-gamma-inducing factors (IL-12 and IL-15) induces a lethal systemic inflammatory response in mice that is dependent on natural killer cells but does not require interferon-gammaJennifer L Biber, Saad Jabbour, Robin Parihar, et al.Blood|January 5, 2008
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gammaSri Vidya Kondadasula, Julie M Roda, Robin Parihar, et al.Blood|December 18, 2004
Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulationRossana Trotta, Robin Parihar, Jianhua Yu, et al.Molecular Therapy. Oncology|June 23, 2025
Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinomaGreyson Biegert, Amanda Rosewell Shaw, Daisuke Morita, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12Charles F Eisenbeis, Gregory B Lesinski, Mirela Anghelina, et al.The Journal of Clinical Investigation|July 17, 2003
The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouseGregory B Lesinski, Mirela Anghelina, Jason Zimmerer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661Gini F Fleming, Neal J Meropol, Gary L Rosner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patientsRobin Parihar, Padma Nadella, Adrian Lewis, et al.Journal for Immunotherapy of Cancer|November 24, 2021
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancerSaisha A Nalawade, Paul Shafer, Pradip Bajgain, et al.Pageof 4